Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2007 3
2008 2
2011 1
2014 1
2021 1
2022 5
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
SEOM-GEICO Clinical Guidelines on cervical cancer (2023).
Manso L, Ramchandani-Vaswani A, Romero I, Sánchez-Lorenzo L, Bermejo-Pérez MJ, Estévez-García P, Fariña-Madrid L, García García Y, Gil-Martin M, Quindós M. Manso L, et al. Among authors: bermejo perez mj. Clin Transl Oncol. 2024 Nov;26(11):2771-2782. doi: 10.1007/s12094-024-03604-3. Epub 2024 Aug 31. Clin Transl Oncol. 2024. PMID: 39215938 Free PMC article.
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina Ginesta MP, Follana P, Pérez-Fidalgo JA, Rodrigues M, Santaballa A, Sabatier R, Bermejo-Pérez MJ, Lotz JP, Pardo B, Marquina G, Sánchez-Lorenzo L, Quindós M, Estévez-García P, Guerra Alía E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A, Selle F. González-Martín A, et al. Among authors: bermejo perez mj. J Clin Oncol. 2024 Sep 18:JCO2400668. doi: 10.1200/JCO.24.00668. Online ahead of print. J Clin Oncol. 2024. PMID: 39292975
Gut and Endometrial Microbiome Dysbiosis: A New Emergent Risk Factor for Endometrial Cancer.
Boutriq S, González-González A, Plaza-Andrades I, Laborda-Illanes A, Sánchez-Alcoholado L, Peralta-Linero J, Domínguez-Recio ME, Bermejo-Pérez MJ, Lavado-Valenzuela R, Alba E, Queipo-Ortuño MI. Boutriq S, et al. Among authors: bermejo perez mj. J Pers Med. 2021 Jul 14;11(7):659. doi: 10.3390/jpm11070659. J Pers Med. 2021. PMID: 34357126 Free PMC article. Review.
Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer.
Baena-Cañada JM, Gámez-Casado S, Rodríguez-Pérez L, Bandera-López C, Mesas-Ruiz A, Campini-Bermejo A, Bernal-Gómez M, Zalabardo-Aguilar M, Calvete-Candenas J, Martínez-Bernal G, Quílez-Cutillas A, Atienza-Cuevas L, García-Rojo M, Benítez-Rodríguez E, Pajares-Hachero B, Bermejo-Pérez MJ. Baena-Cañada JM, et al. Among authors: bermejo perez mj. Med Clin (Barc). 2022 Oct 28;159(8):351-358. doi: 10.1016/j.medcli.2021.11.008. Epub 2022 Feb 16. Med Clin (Barc). 2022. PMID: 35181168 English, Spanish.
The Benefits of a Therapeutic Exercise and Educational Intervention Program on Central Sensitization Symptoms and Pain-Related Fear Avoidance in Breast Cancer Survivors.
Gutiérrez-Sánchez D, Pajares-Hachero BI, Trinidad-Fernández M, Escriche-Escuder A, Iglesias-Campos M, Bermejo-Pérez MJ, Alba-Conejo E, Roldán-Jiménez C, Cuesta-Vargas A. Gutiérrez-Sánchez D, et al. Among authors: bermejo perez mj. Pain Manag Nurs. 2022 Aug;23(4):467-472. doi: 10.1016/j.pmn.2022.01.003. Epub 2022 Mar 9. Pain Manag Nurs. 2022. PMID: 35277360 Free article.
17 results